Veritiv Launched TempSafe RxShield Shipping Canister
The new insulated canister supports the rising mail-order delivery of specialty pharmaceuticals.
Updated on Oct. 6, 2026 in Diabetes
Live Poll
Do you believe the growth of mail-order prescription delivery makes healthcare more accessible for you?
Veritiv Operating Company has introduced the TempSafe RxShield, an insulated shipping canister designed to maintain refrigerated temperatures for 36 hours. The launch comes as mail-order delivery becomes standard for over 60% of specialty pharmacy prescriptions.
Why it matters
The development seeks to optimize storage and lower shipping costs amid a surge in the use of GLP-1 therapies. As more patients manage treatments from home, the demand for reliable cold-chain packaging for temperature-sensitive vials has grown significantly.
The TempSafe RxShield is validated to ISTA 7E thermal performance standards and holds four 10 mL vials. The canister weighs 240 grams and utilizes thin cellulose-based insulation to maintain temperature requirements.
The players
Veritiv Operating Company
A distribution and packaging solutions provider that operates more than 120 facilities across the United States.
The details
The system features a cylindrical design with a foam buffer, a phase change management bottle, and a screw-on lid. By utilizing thin cellulose insulation, the design aims to reduce wasted space and minimize dimensional weight during transit.
Timeline
In 2024, adult GLP-1 usage reached 3 percent.
In 2026, adult GLP-1 usage grew to 11 percent.
The GLP-1 market is projected to reach $190 billion by 2035.
Relevant Data
The introduction of this container follows the documented trend of more than 60% of specialty pharmacy prescriptions now being delivered by mail. It highlights the adaptation of packaging logistics to meet the evolving demands of the pharmaceutical supply chain.
Patients who rely on home delivery for refrigerated medications may experience more consistent cold-chain reliability and reduced transit-related spoilage. This could lead to fewer disruptions in ongoing treatment regimens for those managing conditions like diabetes.
The takeaway
The growth of the GLP-1 market is forcing a transformation in standard pharmaceutical distribution infrastructure. Manufacturers are prioritizing compact, high-efficiency packaging to handle the logistics of cold-chain shipments at scale.
Further reading
For more information on the evolving landscape of care, visit the Diabetes section.
Source note: This article includes information reported by PlasticsToday.
Live Poll
Do you believe the growth of mail-order prescription delivery makes healthcare more accessible for you?
